Malaria,Falciparum

5

Review clinical trials related to Malaria,Falciparum. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

A Study to Assess the Experimental Malaria Vaccines R78C and RH5.1 Combined With R21/Matrix-M (a "Multi-stage" Malaria Vaccine)

This is a Phase Ib age de-escalation, dose escalation, open-label study to assess the safety and immunogenicity of the multi-stage malaria vaccine candidate R21 plus RH5.1 and/or R78C in Matrix-M in adults aged 18-35 years and children aged 5-17 months in Burkina Faso.

Participants needed: 56
Trial details
Phase: Phase 1Age: 5-35Biological sex: AllType: InterventionalSponsor: University of OxfordUpdated: Mar 11, 2026Locations: 1
Eligibility criteria

Group 1: Healthy adult aged 18-35 years at the time of first study vaccination [+4]

Clinically significant congenital abnormalities as judged by the PI or other del... [+22]

Status: Recruiting

An Observational Study to Assess Effectiveness and Safety of The R21/Matrix-M Malaria Vaccine

This is an observational case-control study to assess the effectiveness of the R21/Matrix-M vaccine against severe malaria, clinical malaria (in high transmission perennial areas), and to assess if the R21 vaccine recipients are at an increased risk of deaths (all-cause). Clinical malaria, severe malaria and death (all-cause) cases will be enrolled in study. For each case (severe or death) 4 controls matched for age and neighborhood will be enrolled whereas for clinical malaria case, 1 matched control will be enrolled. 1. Proportion of vaccinated and unvaccinated children amongst Severe Malaria Cases caused by P. falciparum. 2. Proportion of vaccinated and unvaccinated children amongst Clinical Malaria Cases in high-transmission perennial areas caused by P. falciparum. 3. Proportion of vaccinated and unvaccinated children in cases of death (all cause) 4. Exploratory effectiveness endpoint: Proportion of vaccinated and unvaccinated children in the hospitalized clinical and severe malaria cases.

Participants needed: 2,308
Trial details
Age: 5+Biological sex: AllType: ObservationalSponsor: Serum Institute of India Pvt. Ltd.Updated: Aug 13, 2025Locations: 5
Eligibility criteria

Parent/legal guardian/ caregiver not consenting to let the child participate or... [+6]

Status: Recruiting

A Study to Test Experimental Blood Stage Malaria Vaccine in Burkina Faso.

This is a Phase IIb randomised controlled trial of the safety, immunogenicity and efficacy of the blood-stage malaria vaccine candidates RH5.1 in Matrix-MTM and RH5.2-VLP in Matrix-MTM in infants aged 5-17 months in Burkina Faso

Participants needed: 480
Trial details
Phase: Phase 1, Phase 2Age: 5-17Biological sex: AllType: InterventionalSponsor: University of OxfordUpdated: Mar 7, 2025Locations: 1
Eligibility criteria

Healthy infant aged 5-17 months at the time of first study vaccination [+2]

Clinically significant congenital abnormalities as judged by the PI or other del... [+13]

Status: Not yet recruiting

Durability of Protection After Single Immunisation With GA2 Sporozoites (CoGA-Rechallenge)

This study will assess the durability of protection of a single immunisation with the Genetically Attenuated Parasite 2 (GA2) against controlled human malaria infection by rechallenging previously immunised and protected participants from the CoGA study (NCT05468606)

Participants needed: 14
Trial details
Phase: Phase 1Age: 18-35Biological sex: AllType: InterventionalSponsor: Leiden University Medical CenterUpdated: Dec 27, 2024
Eligibility criteria

Participant is aged ≥18 and ≤35 years and in good health. [+9]

For participants of child bearing potential: breastfeeding, or positive serum pr... [+6]

Status: Not yet recruiting

Addressing Asymptomatic Plasmodium Reservoirs to Accelerate Malaria Elimination and Eradication in Rwanda.

The investigators believe that to effectively achieve malaria elimination in Rwanda, it is critical to target the human reservoirs of Plasmodium falciparum using local and readily available Artemisia tea. Asymptomatic infections detectable by PCR are important reservoirs because they often persist for months and harbor gametocytes, the parasite stage infectious to mosquitoes. Lessons learnt from this study will be of critical importance for health decision makers with regard to potential malaria control. MSc and PhD students will be trained and the impact of this research project will be enormous on the socioeconomic transformation of Rwanda.

Participants needed: 125
Trial details
Phase: Phase 2Age: 18-65Biological sex: AllType: InterventionalSponsor: King Faisal Hospital RwandaUpdated: Oct 17, 2023
Eligibility criteria

Confirmed as asymptomatic reservoir of Plasmodium in the community or after comp... [+4]

Have known hypersensitivity to any ingredients of the test treatment. [+3]